Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q2 2025 value amounting to $1.8 million.

  • Crinetics Pharmaceuticals' Other Accumulated Expenses rose 6642.0% to $1.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.8 million, marking a year-over-year increase of 6642.0%. This contributed to the annual value of $901000.0 for FY2024, which is 7242.12% down from last year.
  • As of Q2 2025, Crinetics Pharmaceuticals' Other Accumulated Expenses stood at $1.8 million, which was up 6642.0% from $1.7 million recorded in Q1 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Other Accumulated Expenses peaked at $3.3 million during Q4 2023, and registered a low of $335000.0 during Q4 2022.
  • In the last 5 years, Crinetics Pharmaceuticals' Other Accumulated Expenses had a median value of $925500.0 in 2021 and averaged $1.1 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Other Accumulated Expenses surged by 87522.39% in 2023 and then tumbled by 7242.12% in 2024.
  • Crinetics Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $939000.0 in 2021, then tumbled by 64.32% to $335000.0 in 2022, then soared by 875.22% to $3.3 million in 2023, then plummeted by 72.42% to $901000.0 in 2024, then skyrocketed by 99.67% to $1.8 million in 2025.
  • Its Other Accumulated Expenses was $1.8 million in Q2 2025, compared to $1.7 million in Q1 2025 and $901000.0 in Q4 2024.